|
Revage 670 Treatment Protocol
The Revage670 Laser System uses 30, 670nm laser diodes fixed in a rotating canopy utilizing proprietary algorithms. This system of Rotational Phototherapy™ insures complete and consistent scalp coverage for maximum results. The rotating head is housed in a moveable hood that is positioned directly above the patient’s head. The patient is in a seated position while the hood is lowered onto the patient’s head, approximately 2 cm from the scalp. The close proximity of the laser to the patient’s scalp allows for maximum irradiation and minimal dispersion of the laser light energy. Each patient receives 20 minutes of treatment two times a week for six to twelve months. The FDA has certified the Revage 670 as a class 3 A cosmetic device.
Patient selection is based on an initial medical evaluation to rule out other causes of hair loss. Then we take a series of close-up photographs of the head, followed by a series of 1 cm video microscopic images of the frontal, vertex and temporal hairlines. These pictures are used for before-and-after comparisons when the patient is followed up at three-month intervals.
The Revage 670 is extremely safe. As a LLLL device, it doesn’t emit ablative energy. Hence, there is no risk of injuring the patient’s epidermis or dermis. The laser energy does, however, stimulate blood flow and patients may complain of a transient headache after the first few treatments.
With two 20-minute treatments per week, patients have a nonsurgical, no-risk and safe method for regaining hair. This treatment is commonly combined with traditional medical treatments for even greater effectiveness. Most patients receive six to 12 months of treatments followed by weekly or monthly maintenance treatments. The cost of treatment varies from $3,000 to $5,000 per year, plus the cost of medications.
The Revage 670 is effective in treating androgenetic alopecia and telogen effluvium. Generally, after the first three to six months of treatment, 80 percent of patients with AGA report increased hair density, and nearly all patients with telogen effluvium report complete cessation of shedding. The hair growth continues while patients complete the full one year of treament with the Revage 670 and will taper after 12 months. Most patients will require once a month follow-up treatments in order to maintain their results. All patients taking oral or topical medications are encouraged to continue as well.
|
